SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Peeters, P. Articles by Marynen, P. Search for Related Content PubMed PubMed Citation Articles by Peeters, P. Articles by Marynen, P. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  RAPID COMMUNICATION Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia Pieter Peeters, Sophie D. Raynaud, Jan Cools, Iwona Wlodarska, Josiane Grosgeorge, Patrick Philip, Fabrice Monpoux, Luc Van Rompaey, Mathijs Baens, Herman Van den Berghe, and Peter Marynen From the Center for Human Genetics, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium; Laboratoire de Génétique, Faculté de Médecine, Nice; UEFCT, Hôpital Pasteur, Nice; and Service de Pédiatrie, Hôpital de l'Archet, Nice, France. Translocations in hematologic disease of myeloid or lymphoid origin with breakpoints at chromosome band 12p13 frequently result in rearrangements of the Ets variant gene 6 (ETV6). As a consequence either the ETS DNA-binding domain or the Helix-Loop-Helix (HLH) oligomerization domain of ETV6 is fused to different partner genes. We show here that a t(9; 12)(p24; p13) in a case of early pre-B acute lymphoid leukemia and a t(9; 15; 12)(p24; q15; p13) in atypical chronic myelogenous leukemia in transformation involve the ETV6 gene at 12p13 and the JAK2 gene at 9p24. In each case different fusion mRNAs were found, with only one resulting in an open reading frame for a chimeric protein consisting of the HLH oligomerization domain of ETV6 and the protein tyrosine kinase (PTK) domain of JAK2. The cloning of the complete human JAK2 coding and genomic sequences and of the genomic junction fragments of the translocations allowed a characterization of the different splice events leading to the various mRNAs. JAK2 plays a central role in non-protein tyrosine kinase receptor signaling pathways, which could explain its involvement in malignancies of different hematologic lineages. Besides hop in Drosophila no member of the JAK family has yet been implicated in tumorigenesis. Blood, Vol. 90 No. 7 (October 1), 1997: pp. 2535-2540 © 1997 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo Mol. Cancer Ther., November 1, 2009; 8(11): 3036 - 3045. M B K Lambros, D S P Tan, R L Jones, R Vatcheva, K Savage, N Tamber, K Fenwick, A Mackay, A Ashworth, and J S Reis-Filho Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplication J. Clin. Pathol., July 1, 2009; 62(7): 604 - 612. [Abstract] [Full Text] [PDF] S. Chiaretti and R. Foa T-cell acute lymphoblastic leukemia Haematologica, February 1, 2009; 94(2): 160 - 162. [Full Text] [PDF] R. Burger, S. Le Gouill, Y.-T. Tai, R. Shringarpure, P. Tassone, P. Neri, K. Podar, L. Catley, T. Hideshima, D. Chauhan, et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo Mol. Cancer Ther., January 1, 2009; 8(1): 26 - 35. [Abstract] [Full Text] [PDF] W. F. Tam, T.-L. Gu, J. Chen, B. H. Lee, L. Bullinger, S. Frohling, A. Wang, S. Monti, T. R. Golub, and D. G. Gilliland Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells Blood, September 1, 2008; 112(5): 1981 - 1992. [Abstract] [Full Text] [PDF] J. Sayyah, A. Magis, D. A. Ostrov, R. W. Allan, R. C. Braylan, and P. P. Sayeski Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth Mol. Cancer Ther., August 1, 2008; 7(8): 2308 - 2318. [Abstract] [Full Text] [PDF] C. Hintzen, C. Evers, B. E. Lippok, R. Volkmer, P. C. Heinrich, S. Radtke, and H. M. Hermanns Box 2 Region of the Oncostatin M Receptor Determines Specificity for Recruitment of Janus Kinases and STAT5 Activation J. Biol. Chem., July 11, 2008; 283(28): 19465 - 19477. [Abstract] [Full Text] [PDF] G. Wernig, J. R. Gonneville, B. J. Crowley, M. S. Rodrigues, M. M. Reddy, H. E. Hudon, C. Walz, A. Reiter, K. Podar, Y. Royer, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes Blood, April 1, 2008; 111(7): 3751 - 3759. [Abstract] [Full Text] [PDF] R. Monni, L. Haddaoui, A. Naba, I. Gallais, M. Arpin, P. Mayeux, and F. Moreau-Gachelin Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia Blood, March 15, 2008; 111(6): 3163 - 3172. [Abstract] [Full Text] [PDF] A. Ferrajoli, S. Faderl, Q. Van, P. Koch, D. Harris, Z. Liu, I. Hazan-Halevy, Y. Wang, H. M. Kantarjian, W. Priebe, et al. WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells Cancer Res., December 1, 2007; 67(23): 11291 - 11299. [Abstract] [Full Text] [PDF] A. Tefferi and A. Pardanani Evaluation of 'Increased' Hemoglobin in the JAK2 Mutations Era: A Diagnostic Algorithm Based on Genetic Tests Mayo Clin. Proc., May 1, 2007; 82(5): 599 - 604. [Abstract] [Full Text] [PDF] N. R. dos Santos, D. S. Rickman, A. de Reynies, F. Cormier, M. Williame, C. Blanchard, M.-H. Stern, and J. Ghysdael Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia Blood, May 1, 2007; 109(9): 3972 - 3981. [Abstract] [Full Text] [PDF] S. Malinge, R. Ben-Abdelali, C. Settegrana, I. Radford-Weiss, M. Debre, K. Beldjord, E. A. Macintyre, J.-L. Villeval, W. Vainchenker, R. Berger, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia Blood, March 1, 2007; 109(5): 2202 - 2204. [Abstract] [Full Text] [PDF] E. Lierman and J. Cools ETV6 and PDGFRB: a license to fuse Haematologica, February 1, 2007; 92(2): 145 - 147. [Full Text] [PDF] X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li, S. B. Krantz, X. Fu, and Z. J. Zhao JAK2V617F: prevalence in a large Chinese hospital population Blood, January 1, 2007; 109(1): 339 - 342. [Abstract] [Full Text] [PDF] J. A. Kennedy, F. Barabe, B. J. Patterson, J. Bayani, J. A. Squire, D. L. Barber, and J. E. Dick Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo PNAS, November 7, 2006; 103(45): 16930 - 16935. [Abstract] [Full Text] [PDF] J. H. Kurzer, P. Saharinen, O. Silvennoinen, and C. Carter-Su Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State. Mol. Cell. Biol., September 1, 2006; 26(17): 6381 - 6394. [Abstract] [Full Text] [PDF] F. G. Rucker, L. Bullinger, C. Schwaenen, D. B. Lipka, S. Wessendorf, S. Frohling, M. Bentz, S. Miller, C. Scholl, R. F. Schlenk, et al. Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization J. Clin. Oncol., August 20, 2006; 24(24): 3887 - 3894. [Abstract] [Full Text] [PDF] C. Walz, B. J. Crowley, H. E. Hudon, J. L. Gramlich, D. S. Neuberg, K. Podar, J. D. Griffin, and M. Sattler Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition J. Biol. Chem., June 30, 2006; 281(26): 18177 - 18183. [Abstract] [Full Text] [PDF] A. M. Mazurkiewicz-Munoz, L. S. Argetsinger, J.-L. K. Kouadio, A. Stensballe, O. N. Jensen, J. M. Cline, and C. Carter-Su Phosphorylation of JAK2 at Serine 523: a Negative Regulator of JAK2 That Is Stimulated by Growth Hormone and Epidermal Growth Factor. Mol. Cell. Biol., June 1, 2006; 26(11): 4052 - 4062. [Abstract] [Full Text] [PDF] I. S. Lucet, E. Fantino, M. Styles, R. Bamert, O. Patel, S. E. Broughton, M. Walter, C. J. Burns, H. Treutlein, A. F. Wilks, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor Blood, January 1, 2006; 107(1): 176 - 183. [Abstract] [Full Text] [PDF] X. Lu, R. Levine, W. Tong, G. Wernig, Y. Pikman, S. Zarnegar, D. G. Gilliland, and H. Lodish Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation PNAS, December 27, 2005; 102(52): 18962 - 18967. [Abstract] [Full Text] [PDF] J. Jelinek, Y. Oki, V. Gharibyan, C. Bueso-Ramos, J. T. Prchal, S. Verstovsek, M. Beran, E. Estey, H. M. Kantarjian, and J.-P. J. Issa JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood, November 15, 2005; 106(10): 3370 - 3373. [Abstract] [Full Text] [PDF] R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia Blood, November 15, 2005; 106(10): 3377 - 3379. [Abstract] [Full Text] [PDF] L. M. Scott, P. J. Campbell, E. J. Baxter, T. Todd, P. Stephens, S. Edkins, R. Wooster, M. R. Stratton, P. A. Futreal, and A. R. Green The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders Blood, October 15, 2005; 106(8): 2920 - 2921. [Full Text] [PDF] A. V. Jones, S. Kreil, K. Zoi, K. Waghorn, C. Curtis, L. Zhang, J. Score, R. Seear, A. J. Chase, F. H. Grand, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood, September 15, 2005; 106(6): 2162 - 2168. [Abstract] [Full Text] [PDF] S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295. [Abstract] [Full Text] [PDF] F. Nakamura, Y. Nakamura, K. Maki, Y. Sato, and K. Mitani Cloning and Characterization of the Novel Chimeric Gene TEL/PTPRR in Acute Myelogenous Leukemia with inv(12)(p13q13) Cancer Res., August 1, 2005; 65(15): 6612 - 6621. [Abstract] [Full Text] [PDF] A. Tefferi and D. G. Gilliland The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis Mayo Clin. Proc., July 1, 2005; 80(7): 947 - 958. [Abstract] [PDF] V. Moucadel and S. N. Constantinescu Differential STAT5 Signaling by Ligand-dependent and Constitutively Active Cytokine Receptors J. Biol. Chem., April 8, 2005; 280(14): 13364 - 13373. [Abstract] [Full Text] [PDF] A. Reiter, C. Walz, A. Watmore, C. Schoch, I. Blau, B. Schlegelberger, U. Berger, N. Telford, S. Aruliah, J. A. Yin, et al. The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2 Cancer Res., April 1, 2005; 65(7): 2662 - 2667. [Abstract] [Full Text] [PDF] T. Maeda, F. Yagasaki, M. Ishikawa, N. Takahashi, and M. Bessho Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML Blood, March 1, 2005; 105(5): 2115 - 2123. [Abstract] [Full Text] [PDF] M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies Blood, January 1, 2005; 105(1): 22 - 30. [Abstract] [Full Text] [PDF] K. W. Harder, C. Quilici, E. Naik, M. Inglese, N. Kountouri, A. Turner, K. Zlatic, D. M. Tarlinton, and M. L. Hibbs Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1 Blood, December 15, 2004; 104(13): 3901 - 3910. [Abstract] [Full Text] [PDF] N. Schick, E. J. Oakeley, N. E. Hynes, and A. Badache TEL/ETV6 Is a Signal Transducer and Activator of Transcription 3 (Stat3)-induced Repressor of Stat3 Activity J. Biol. Chem., September 10, 2004; 279(37): 38787 - 38796. [Abstract] [Full Text] [PDF] L. O. Flowers, H. M. Johnson, M. G. Mujtaba, M. R. Ellis, S. M. I. Haider, and P. S. Subramaniam Characterization of a Peptide Inhibitor of Janus Kinase 2 That Mimics Suppressor of Cytokine Signaling 1 Function J. Immunol., June 15, 2004; 172(12): 7510 - 7518. [Abstract] [Full Text] [PDF] C. E. Tognon, C. D. Mackereth, A. M. Somasiri, L. P. McIntosh, and P. H. B. Sorensen Mutations in the SAM Domain of the ETV6-NTRK3 Chimeric Tyrosine Kinase Block Polymerization and Transformation Activity Mol. Cell. Biol., June 1, 2004; 24(11): 4636 - 4650. [Abstract] [Full Text] [PDF] J. H. Kurzer, L. S. Argetsinger, Y.-J. Zhou, J.-L. K. Kouadio, J. J. O'Shea, and C. Carter-Su Tyrosine 813 Is a Site of JAK2 Autophosphorylation Critical for Activation of JAK2 by SH2-B{beta} Mol. Cell. Biol., May 15, 2004; 24(10): 4557 - 4570. [Abstract] [Full Text] [PDF] K. J. Smith, E. Jacobson, S. Hamza, and H. Skelton Unexplained Hypereosinophilia and the Need for Cytogenetic and Molecular Genetic Analyses Arch Dermatol, May 1, 2004; 140(5): 584 - 588. [Abstract] [Full Text] [PDF] D. W. Sternberg and D. G. Gilliland The Role of Signal Transducer and Activator of Transcription Factors in Leukemogenesis J. Clin. Oncol., January 15, 2004; 22(2): 361 - 371. [Abstract] [Full Text] [PDF] M. Sattler, L. R. Quinnan, Y. B. Pride, J. L. Gramlich, S. C. Chu, G. C. Even, S.-K. Kraeft, L. B. Chen, and R. Salgia 2-Methoxyestradiol alters cell motility, migration, and adhesion Blood, July 1, 2003; 102(1): 289 - 296. [Abstract] [Full Text] [PDF] M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler Signal transducer and activator of transcription proteins in leukemias Blood, April 15, 2003; 101(8): 2940 - 2954. [Abstract] [Full Text] [PDF] J. Cools, D. J. DeAngelo, J. Gotlib, E. H. Stover, R. D. Legare, J. Cortes, J. Kutok, J. Clark, I. Galinsky, J. D. Griffin, et al. A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome N. Engl. J. Med., March 27, 2003; 348(13): 1201 - 1214. [Abstract] [Full Text] [PDF] F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF] F. Giordanetto and R. T. Kroemer Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7 Protein Eng. Des. Sel., September 1, 2002; 15(9): 727 - 737. [Abstract] [Full Text] [PDF] J. M.-Y. Ho, M. H.-H. Nguyen, J. K. Dierov, K. M. Badger, B. K. Beattie, P. Tartaro, R. Haq, B. W. Zanke, M. P. Carroll, and D. L. Barber TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways Blood, July 30, 2002; 100(4): 1438 - 1448. [Abstract] [Full Text] [PDF] B. Li, J. C. Ruiz, and K. T. Chun CUL-4A Is Critical for Early Embryonic Development Mol. Cell. Biol., July 15, 2002; 22(14): 4997 - 5005. [Abstract] [Full Text] [PDF] A. Slupianek, G. Hoser, I. Majsterek, A. Bronisz, M. Malecki, J. Blasiak, R. Fishel, and T. Skorski Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis Mol. Cell. Biol., June 15, 2002; 22(12): 4189 - 4201. [Abstract] [Full Text] [PDF] J. Cools, N. Mentens, M. D. Odero, P. Peeters, I. Wlodarska, M. Delforge, A. Hagemeijer, and P. Marynen Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13) Blood, March 1, 2002; 99(5): 1776 - 1784. [Abstract] [Full Text] [PDF] F. Onida, H. M. Kantarjian, T. L. Smith, G. Ball, M. J. Keating, E. H. Estey, A. B. Glassman, M. Albitar, M. I. Kwari, and M. Beran Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients Blood, February 1, 2002; 99(3): 840 - 849. [Abstract] [Full Text] [PDF] L. M. Kelly, Q. Liu, J. L. Kutok, I. R. Williams, C. L. Boulton, and D. G. Gilliland FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model Blood, January 1, 2002; 99(1): 310 - 318. [Abstract] [Full Text] [PDF] F. Yagasaki, D. Wakao, Y. Yokoyama, Y. Uchida, I. Murohashi, H. Kayano, M. Taniwaki, A. Matsuda, and M. Bessho Fusion of ETV6 to Fibroblast Growth Factor Receptor 3 in Peripheral T-Cell Lymphoma with a t(4;12)(p16;p13) Chromosomal Translocation Cancer Res., December 1, 2001; 61(23): 8371 - 8374. [Abstract] [Full Text] [PDF] J. Schwaller, E. Anastasiadou, D. Cain, J. Kutok, S. Wojiski, I. R. Williams, R. LaStarza, B. Crescenzi, D. W. Sternberg, P. Andreasson, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor {beta} gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22) Blood, June 15, 2001; 97(12): 3910 - 3918. [Abstract] [Full Text] [PDF] J. Frantsve, J. Schwaller, D. W. Sternberg, J. Kutok, and D. G. Gilliland Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation Mol. Cell. Biol., May 15, 2001; 21(10): 3547 - 3557. [Abstract] [Full Text] K. Okuda, E. Weisberg, D. G. Gilliland, and J. D. Griffin ARG tyrosine kinase activity is inhibited by STI571 Blood, April 15, 2001; 97(8): 2440 - 2448. [Abstract] [Full Text] [PDF] D. G. Gilliland The Diverse Role of the ETS Family of Transcription Factors in Cancer: Commentary re: B. Davidson, Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma. Clin. Cancer Res., 7: 551-557, 2001. Clin. Cancer Res., March 1, 2001; 7(3): 451 - 453. [Full Text] Y. Kuno, A. Abe, N. Emi, M. Iida, T. Yokozawa, M. Towatari, M. Tanimoto, and H. Saito Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12) Blood, February 15, 2001; 97(4): 1050 - 1055. [Abstract] [Full Text] [PDF] F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick Acute Myeloid Leukemia Hematology, January 1, 2001; 2001(1): 62 - 86. [Abstract] [Full Text] [PDF] A. Buijs, L. van Rompaey, A. C. Molijn, J. N. Davis, A. C. O. Vertegaal, M. D. Potter, C. Adams, S. van Baal, E. C. Zwarthoff, M. F. Roussel, et al. The MN1-TEL Fusion Protein, Encoded by the Translocation (12;22)(p13;q11) in Myeloid Leukemia, Is a Transcription Factor with Transforming Activity Mol. Cell. Biol., December 15, 2000; 20(24): 9281 - 9293. [Abstract] [Full Text] J. J O'Shea, R. Visconti, T. P Cheng, and M. Gadina Jaks and Stats as therapeutic targets Ann Rheum Dis, November 1, 2000; 59(90001): i115 - 118. [Abstract] [Full Text] [PDF] R. Fenrick, L. Wang, J. Nip, J. M. Amann, R. J. Rooney, J. Walker-Daniels, H. C. Crawford, D. L. Hulboy, M. S. Kinch, L. M. Matrisian, et al. TEL, a Putative Tumor Suppressor, Modulates Cell Growth and Cell Morphology of Ras-Transformed Cells While Repressing the Transcription of stromelysin-1 Mol. Cell. Biol., August 15, 2000; 20(16): 5828 - 5839. [Abstract] [Full Text] S. Kulkarni, C. Heath, S. Parker, A. Chase, S. Iqbal, C. F. Pocock, J. Kaeda, K. Cwynarski, J. M. Goldman, and N. C. P. Cross Fusion of H4/D10S170 to the Platelet-derived Growth Factor Receptor {beta} in BCR-ABL-negative Myeloproliferative Disorders with a t(5;10)(q33;q21) Cancer Res., July 1, 2000; 60(13): 3592 - 3598. [Abstract] [Full Text] C. Carron, F. Cormier, A. Janin, V. Lacronique, M. Giovannini, M.-T. Daniel, O. Bernard, and J. Ghysdael TEL-JAK2 transgenic mice develop T-cell leukemia Blood, June 15, 2000; 95(12): 3891 - 3899. [Abstract] [Full Text] [PDF] V. Lacronique, A. Boureux, R. Monni, S. Dumon, M. Mauchauffe, P. Mayeux, F. Gouilleux, R. Berger, S. Gisselbrecht, J. Ghysdael, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells Blood, March 15, 2000; 95(6): 2076 - 2083. [Abstract] [Full Text] [PDF] Y. Iijima, T. Ito, T. Oikawa, M. Eguchi, M. Eguchi-Ishimae, N. Kamada, K. Kishi, S. Asano, Y. Sakaki, and Y. Sato A new ETV6 / TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation Blood, March 15, 2000; 95(6): 2126 - 2131. [Abstract] [Full Text] [PDF] K. Kas, E. Finger, F. Grall, X. Gu, Y. Akbarali, J. Boltax, A. Weiss, P. Oettgen, R. Kapeller, and T. A. Libermann ESE-3, a Novel Member of an Epithelium-specific Ets Transcription Factor Subfamily, Demonstrates Different Target Gene Specificity from ESE-1 J. Biol. Chem., January 28, 2000; 275(4): 2986 - 2998. [Abstract] [Full Text] [PDF] A. C. Ward, I. Touw, and A. Yoshimura The Jak-Stat pathway in normal and perturbed hematopoiesis Blood, January 1, 2000; 95(1): 19 - 29. [Full Text] [PDF] G. Cazzaniga, S. Tosi, A. Aloisi, G. Giudici, M. Daniotti, P. Pioltelli, L. Kearney, and A. Biondi The Tyrosine Kinase Abl-Related Gene ARG Is Fused to ETV6 in an AML-M4Eo Patient With a t(1;12)(q25;p13): Molecular Cloning of Both Reciprocal Transcripts Blood, December 15, 1999; 94(12): 4370 - 4373. [Abstract] [Full Text] [PDF] B. P. Pollack, S. V. Kotenko, W. He, L. S. Izotova, B. L. Barnoski, and S. Pestka The Human Homologue of the Yeast Proteins Skb1 and Hsl7p Interacts with Jak Kinases and Contains Protein Methyltransferase Activity J. Biol. Chem., October 29, 1999; 274(44): 31531 - 31542. [Abstract] [Full Text] [PDF] R. G. Lopez, C. Carron, C. Oury, P. Gardellin, O. Bernard, and J. Ghysdael TEL Is a Sequence-specific Transcriptional Repressor J. Biol. Chem., October 15, 1999; 274(42): 30132 - 30138. [Abstract] [Full Text] [PDF] P. Oettgen, K. Kas, A. Dube, X. Gu, F. Grall, U. Thamrongsak, Y. Akbarali, E. Finger, J. Boltax, G. Endress, et al. Characterization of ESE-2, a Novel ESE-1-related Ets Transcription Factor That Is Restricted to Glandular Epithelium and Differentiated Keratinocytes J. Biol. Chem., October 8, 1999; 274(41): 29439 - 29452. [Abstract] [Full Text] [PDF] J. Cools, C. Bilhou-Nabera, I. Wlodarska, C. Cabrol, P. Talmant, P. Bernard, A. Hagemeijer, and P. Marynen Fusion of a Novel Gene, BTL, to ETV6 in Acute Myeloid Leukemias With a t(4;12)(q11-q12;p13) Blood, September 1, 1999; 94(5): 1820 - 1824. [Abstract] [Full Text] [PDF] T. S. Ross and D. G. Gilliland Transforming Properties of the Huntingtin Interacting Protein 1/ Platelet-derived Growth Factor beta Receptor Fusion Protein J. Biol. Chem., August 6, 1999; 274(32): 22328 - 22336. [Abstract] [Full Text] [PDF] J. M.-Y. Ho, B. K. Beattie, J. A. Squire, D. A. Frank, and D. L. Barber Fusion of the ets Transcription Factor TEL to Jak2 Results in Constitutive Jak-Stat Signaling Blood, June 15, 1999; 93(12): 4354 - 4364. [Abstract] [Full Text] [PDF] R. Y. Liu, C. Fan, R. Garcia, R. Jove, and K. S. Zuckerman Constitutive Activation of the JAK2/STAT5 Signal Transduction Pathway Correlates With Growth Factor Independence of Megakaryocytic Leukemic Cell Lines Blood, April 1, 1999; 93(7): 2369 - 2379. [Abstract] [Full Text] [PDF] C.-B. Liu, T. Itoh, K.-i. Arai, and S. Watanabe Constitutive Activation of JAK2 Confers Murine Interleukin-3-independent Survival and Proliferation of BA/F3 Cells J. Biol. Chem., March 5, 1999; 274(10): 6342 - 6349. [Abstract] [Full Text] [PDF] M. Eguchi, M. Eguchi-Ishimae, A. Tojo, K. Morishita, K. Suzuki, Y. Sato, S. Kudoh, K. Tanaka, M. Setoyama, F. Nagamura, et al. Fusion of ETV6 to Neurotrophin-3 Receptor TRKC in Acute Myeloid Leukemia With t(12;15)(p13;q25) Blood, February 15, 1999; 93(4): 1355 - 1363. [Abstract] [Full Text] [PDF] A. Chase, A. Reiter, L. Burci, G. Cazzaniga, A. Biondi, J. Pickard, I. A.G. Roberts, J. M. Goldman, and N. C.P. Cross Fusion of ETV6 to the Caudal-Related Homeobox Gene CDX2 in Acute Myeloid Leukemia With the t(12;13)(p13;q12) Blood, February 1, 1999; 93(3): 1025 - 1031. [Abstract] [Full Text] [PDF] S. J. Corey and S. M. Anderson Src-Related Protein Tyrosine Kinases in Hematopoiesis Blood, January 1, 1999; 93(1): 1 - 14. [Full Text] [PDF] N. N. Danial, J. A. Losman, T. Lu, N. Yip, K. Krishnan, J. Krolewski, S. P. Goff, J. Y. J. Wang, and P. B. Rothman Direct Interaction of Jak1 and v-Abl Is Required for v-Abl-Induced Activation of STATs and Proliferation Mol. Cell. Biol., November 1, 1998; 18(11): 6795 - 6804. [Abstract] [Full Text] B. P. Rubin, C.-J. Chen, T. W. Morgan, S. Xiao, H. E. Grier, H. P. Kozakewich, A. R. Perez-Atayde, and J. A. Fletcher Congenital Mesoblastic Nephroma t(12;15) Is Associated with ETV6-NTRK3 Gene Fusion : Cytogenetic and Molecular Relationship to Congenital (Infantile)Fibrosarcoma Am. J. Pathol., November 1, 1998; 153(5): 1451 - 1458. [Abstract] [Full Text] [PDF] D. A. Harrison, P. E. McCoon, R. Binari, M. Gilman, and N. Perrimon Drosophila unpaired encodes a secreted protein that activates the JAK signaling pathway Genes & Dev., October 15, 1998; 12(20): 3252 - 3263. [Abstract] [Full Text] C. M. Slupsky, L. N. Gentile, L. W. Donaldson, C. D. Mackereth, J. J. Seidel, B. J. Graves, and L. P. McIntosh Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphorylation site PNAS, October 13, 1998; 95(21): 12129 - 12134. [Abstract] [Full Text] [PDF] A. Reiter, J. Sohal, S. Kulkarni, A. Chase, D. H.C. Macdonald, R. C.T. Aguiar, C. Goncalves, J. M. Hernandez, B. A. Jennings, J. M. Goldman, et al. Consistent Fusion of ZNF198 to the Fibroblast Growth Factor Receptor-1 in the t(8;13)(p11;q12) Myeloproliferative Syndrome Blood, September 1, 1998; 92(5): 1735 - 1742. [Abstract] [Full Text] [PDF] L. C. Wang, W. Swat, Y. Fujiwara, L. Davidson, J. Visvader, F. Kuo, F. W. Alt, D. G. Gilliland, T. R. Golub, and S. H. Orkin The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow Genes & Dev., August 1, 1998; 12(15): 2392 - 2402. [Abstract] [Full Text] M. Onishi, T. Nosaka, K. Misawa, A. L.-F. Mui, D. Gorman, M. McMahon, A. Miyajima, and T. Kitamura Identification and Characterization of a Constitutively Active STAT5 Mutant That Promotes Cell Proliferation Mol. Cell. Biol., July 1, 1998; 18(7): 3871 - 3879. [Abstract] [Full Text] T. S. Ross, O. A. Bernard, R. Berger, and D. G. Gilliland Fusion of Huntingtin Interacting Protein 1 to Platelet-Derived Growth Factor beta  Receptor (PDGFbeta R) in Chronic Myelomonocytic Leukemia With t(5;7)(q33;q11.2) Blood, June 15, 1998; 91(12): 4419 - 4426. [Abstract] [Full Text] [PDF] V. Lacronique, A. Boureux, V. Della Valle, H. Poirel, C. T. Quang, M. Mauchauffé, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, et al. A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia Science, November 14, 1997; 278(5341): 1309 - 1312. [Abstract] [Full Text] X. Gu, B.-H. Shin, Y. Akbarali, A. Weiss, J. Boltax, P. Oettgen, and T. A. Libermann Tel-2 Is a Novel Transcriptional Repressor Related to the Ets Factor Tel/ETV-6 J. Biol. Chem., March 16, 2001; 276(12): 9421 - 9436. [Abstract] [Full Text] [PDF] S. Kamizono, T. Hanada, H. Yasukawa, S. Minoguchi, R. Kato, M. Minoguchi, K. Hattori, S. Hatakeyama, M. Yada, S. Morita, et al. The SOCS Box of SOCS-1 Accelerates Ubiquitin-dependent Proteolysis of TEL-JAK2 J. Biol. Chem., April 13, 2001; 276(16): 12530 - 12538. [Abstract] [Full Text] [PDF] M. H.-H. Nguyen, J. M.-Y. Ho, B. K. Beattie, and D. L. Barber TEL-JAK2 Mediates Constitutive Activation of the Phosphatidylinositol 3'-Kinase/Protein Kinase B Signaling Pathway J. Biol. Chem., August 24, 2001; 276(35): 32704 - 32713. [Abstract] [Full Text] [PDF] S. Sarkar, B. P. Pollack, K.-T. Lin, S. V. Kotenko, J. R. Cook, A. Lewis, and S. Pestka hTid-1, a Human DnaJ Protein, Modulates the Interferon Signaling Pathway J. Biol. Chem., December 21, 2001; 276(52): 49034 - 49042. [Abstract] [Full Text] [PDF] F. Salomon-Nguyen, V. Della-Valle, M. Mauchauffe, M. Busson-Le Coniat, J. Ghysdael, R. Berger, and O. A. Bernard The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion PNAS, June 6, 2000; 97(12): 6757 - 6762. [Abstract] [Full Text] [PDF]

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020